950160.KQ Kolon TissueGene, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
08:24
Jun 17
Jun 17
Biotech rebounding on cleaned credit
KOSDAQ biotech stocks have been heavily depressed with margin debt cleaned out ('empty house'), and are now rebounding. The move is led by DND Pharmatech on technology export expectations and other names like ABL Bio, Olix, and Kolon TissueGene are following. The chart setups suggest a significant bounce can occur once a catalyst lands.
MED
00:00
May 16
May 16
Buy Kolon Tissue after breakout pullback.
Kolon Tissue Gene broke its all-time high and immediately pulled back, a pattern that has previously been followed by a further move higher after a 2-3 week consolidation. The speaker suggests buying 2-3 weeks after the breakout and pullback.
MED
03:42
May 12
May 12
Kolon TissueGene is a biotech catalyst.
Kolon TissueGene is a key biotech catalyst. Upcoming phase 3 data for its knee osteoarthritis treatment (Invossa) in the U.S. could drive the stock significantly and lift the entire Korean biotech sector. The stock is in a good technical position after breaking out.
HIGH
About 950160.KQ Analyst Coverage
Buzzberg tracks 950160.KQ (Kolon TissueGene, Inc.) across 2 sources. 3 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (100%). 3 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Lee Kwon-hee, Park Se-ik, Jang Woo-jin.